EU/3/07/437: Orphan designation for the treatment of Duchenne muscular dystrophy

idebenone

Table of contents

Overview

On 20 March 2007, orphan designation (EU/3/07/437) was granted by the European Commission to Santhera Pharmaceuticals (Deutschland) GmbH, Germany, for idebenone for the treatment of Duchenne muscular dystrophy.

The name of the sponsor changed to Santhera Pharmaceuticals (Deutschland) GmbH in September 2010.

Key facts

Active substance
idebenone
Intented use
Treatment of Duchenne muscular dystrophy
Orphan designation status
Positive
EU designation number
EU/3/07/437
Date of designation
20/03/2007
Sponsor
Santhera Pharmaceuticals (Deutschland) GmbH
Marie-Curie Strasse 8
D-79539 Lörrach
Germany
Tel. +49 7621 1690200
Fax +49 7621 1690201
E-mail: office@santhera.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating